Arima, Mitsuru
Nakao, Shintaro
Kaizu, Yoshihiro
Wada, Iori
Yamaguchi, Muneo
Fujiwara, Kohta
Akiyama, Masato
Stitt, Alan W.
Sonoda, Koh-Hei
Funding for this research was provided by:
JSPS KAKENHI (19K18846)
JSPS KAKENHI (20K09829)
Article History
Received: 24 October 2020
Accepted: 17 December 2020
First Online: 18 February 2021
Change Date: 7 June 2021
Change Type: Correction
Change Details: A Correction to this paper has been published:
Change Details: https://doi.org/10.1038/s41598-021-91789-w
Competing interests
: S. Nakao: consulting fee by Kowa; travel reimbursements and speaker fees by Novartis, Bayer Pharma, Canon Inc., Santen Pharmaceutical, Kowa, Senju Pharmaceutical, Ono Pharmaceutical, and MSD. K.H. Sonoda: consulting fees by Kowa, JT, and AbbVie; travel reimbursements and speaker fees by Novartis, Bayer Pharma, Canon Inc., Santen Pharmaceutical, Kowa, Senju Pharmaceutical, Ono Pharmaceutical, MSD, HOYA, Wakamoto, AMO, Alcon, Otsuka Pharmaceutical, AbbVie Eisai, Nidek, Topcon, Novo Nordisk, Mitsubishi Tanabe Pharma, Sumitomo Dainippon Pharma, and Astellas. The following authors have no financial disclosures: M. Arima, Y. Kaizu, I. Wada, M. Yamaguchi, K. Fujiwara, M. Akiyama, and A.W. Stitt.